Literature DB >> 17160013

Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.

W M Tong1, Y G Yang, W H Cao, D Galendo, L Frappart, Y Shen, Z Q Wang.   

Abstract

The DNA strand break-binding molecule, poly(ADP-ribose) polymerase-1 (PARP-1), plays a role in DNA repair, chromosomal stability, transcription and cell death. Accumulating evidence suggests that dysfunction of PARP-1 contributes to tumorigenesis. Here, we report that PARP-1 deficiency causes mammary carcinoma formation in female mice, and that the introduction of Trp53 mutations accelerates the onset and shortens the latency of mammary tumorigenesis. We show that PARP-1 deficiency results in chromosomal aneuploidy and centrosome amplification, which are substantiated by the inactivation of Trp53 in primary mammary epithelial (PME) cells. In addition, PARP-1 deficiency compromises p53 activation and impairs BRCA1 recruitment to the sites of DNA damage in PME cells. PARP-1 complementation partly rescues the defective DNA damage response mediated by p53 and BRCA1. The present study thus identifies a role of PARP-1 in suppressing mammary tumorigenesis in vivo and suggests that dysfunction of PARP-1 may be a risk factor for breast cancer in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160013     DOI: 10.1038/sj.onc.1210156

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  The role of PARP1 in the DNA damage response and its application in tumor therapy.

Authors:  Zhifeng Wang; Fengli Wang; Tieshan Tang; Caixia Guo
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

Review 2.  Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy.

Authors:  A Ogden; P C G Rida; R Aneja
Journal:  Cell Death Differ       Date:  2012-06-01       Impact factor: 15.828

3.  PARP-1 and PARP-2: New players in tumour development.

Authors:  José Yelamos; Jordi Farres; Laura Llacuna; Coral Ampurdanes; Juan Martin-Caballero
Journal:  Am J Cancer Res       Date:  2011-01-08       Impact factor: 6.166

Review 4.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

5.  Establishment of primary mouse lung adenocarcinoma cell culture.

Authors:  Shuli Luo; Mei Sun; Rui Jiang; Guan Wang; Xinyi Zhang
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967

Review 6.  Mammary cancer susceptibility: human genes and rodent models.

Authors:  Claude Szpirer; Josiane Szpirer
Journal:  Mamm Genome       Date:  2007-12-01       Impact factor: 2.957

Review 7.  Exploiting synthetic lethal interactions for targeted cancer therapy.

Authors:  H Christian Reinhardt; Hai Jiang; Michael T Hemann; Michael B Yaffe
Journal:  Cell Cycle       Date:  2009-10-01       Impact factor: 4.534

8.  Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.

Authors:  Francine Durocher; Yvan Labrie; Geneviève Ouellette; Jacques Simard
Journal:  J Hum Genet       Date:  2007-10-18       Impact factor: 3.172

9.  Modulatory effects of alpha- and gamma-tocopherols on 4-hydroxyestradiol induced oxidative stresses in MCF-10A breast epithelial cells.

Authors:  Eun-Ju Lee; Seung-Yeon Oh; Mi-Kyung Kim; Sei Hyun Ahn; Byung Ho Son; Mi-Kyung Sung
Journal:  Nutr Res Pract       Date:  2009-09-30       Impact factor: 1.926

10.  PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

Authors:  Kristine M Frizzell; W Lee Kraus
Journal:  Breast Cancer Res       Date:  2009-11-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.